Rigosertib Sodium is a synthetic benzyl styryl sulfone and kinase inhibitor investigated for its potential to treat various malignancies, including myelodysplastic syndromes and several solid tumors. By… Read more
Rigosertib Sodium is a synthetic benzyl styryl sulfone and kinase inhibitor investigated for its potential to treat various malignancies, including myelodysplastic syndromes and several solid tumors. By targeting pathways such as PI3K/Akt and PLK1, this compound serves as a critical focus in oncology research. The category includes a range of high-quality Rigosertib Sodium reference standards, including identified impurities, metabolites, and stable isotope labelled compounds, which are essential for rigorous pharmaceutical analysis. These materials support laboratories in conducting comprehensive impurity profiling, method validation, and routine quality control testing to ensure data integrity. Pharmaceutical researchers rely on these characterized standards to identify degradation products, establish assay protocols, and maintain compliance with regulatory requirements throughout the drug development lifecycle. By utilizing these precise analytical tools, scientists can accurately assess the stability, potency, and purity of drug formulations during the research and development process.